Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials

Glucans are part of a group of biologically active natural molecules and are steadily gaining strong attention not only as an important food supplement, but also as an immunostimulant and potential drug. This paper represents an up-to-date review of glucans (β-1,3-glucans) and their role in various...

Descripción completa

Detalles Bibliográficos
Autores principales: Vetvicka, Vaclav, Vannucci, Luca, Sima, Petr, Richter, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479769/
https://www.ncbi.nlm.nih.gov/pubmed/30935016
http://dx.doi.org/10.3390/molecules24071251
_version_ 1783413421581008896
author Vetvicka, Vaclav
Vannucci, Luca
Sima, Petr
Richter, Josef
author_facet Vetvicka, Vaclav
Vannucci, Luca
Sima, Petr
Richter, Josef
author_sort Vetvicka, Vaclav
collection PubMed
description Glucans are part of a group of biologically active natural molecules and are steadily gaining strong attention not only as an important food supplement, but also as an immunostimulant and potential drug. This paper represents an up-to-date review of glucans (β-1,3-glucans) and their role in various immune reactions and the treatment of cancer. With more than 80 clinical trials evaluating their biological effects, the question is not if glucans will move from food supplement to widely accepted drug, but how soon.
format Online
Article
Text
id pubmed-6479769
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64797692019-04-30 Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials Vetvicka, Vaclav Vannucci, Luca Sima, Petr Richter, Josef Molecules Review Glucans are part of a group of biologically active natural molecules and are steadily gaining strong attention not only as an important food supplement, but also as an immunostimulant and potential drug. This paper represents an up-to-date review of glucans (β-1,3-glucans) and their role in various immune reactions and the treatment of cancer. With more than 80 clinical trials evaluating their biological effects, the question is not if glucans will move from food supplement to widely accepted drug, but how soon. MDPI 2019-03-30 /pmc/articles/PMC6479769/ /pubmed/30935016 http://dx.doi.org/10.3390/molecules24071251 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vetvicka, Vaclav
Vannucci, Luca
Sima, Petr
Richter, Josef
Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials
title Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials
title_full Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials
title_fullStr Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials
title_full_unstemmed Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials
title_short Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials
title_sort beta glucan: supplement or drug? from laboratory to clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479769/
https://www.ncbi.nlm.nih.gov/pubmed/30935016
http://dx.doi.org/10.3390/molecules24071251
work_keys_str_mv AT vetvickavaclav betaglucansupplementordrugfromlaboratorytoclinicaltrials
AT vannucciluca betaglucansupplementordrugfromlaboratorytoclinicaltrials
AT simapetr betaglucansupplementordrugfromlaboratorytoclinicaltrials
AT richterjosef betaglucansupplementordrugfromlaboratorytoclinicaltrials

Ejemplares similares